|
|
| The Leukemia & Lymphoma
Society (LLS) is pleased to offer Hematologic
Cancer News, an eNewsletter for oncology
professionals. Each month, the newsletter will
inform you about professional education
programs on leukemia, lymphoma, myeloma and
myelodysplastic syndromes, CEU opportunities,
hematologic cancer news and research updates,
all in one convenient
place.
| |
 |
|
|
|
Ongoing
Professional Education
Programs ::READ
MORE::
.....................................................................................................................................
Featured
Material
:: READ
MORE::
.....................................................................................................................................
Upcoming
Teleconferences
::READ
MORE::
.....................................................................................................................................
Patient Question of the
Month
::READ
MORE::
| |
|
Here to
Help
For
even more information, regularly visit the
LLS Web site,
www.LLS.org
,
where many of our education programs are
archived free of charge for convenient access
24/7.
If you haven't found what you're
looking for in Hematologic Cancer News,
please call our Information Resource Center
(IRC) to speak with a trained information
specialist. IRC staff are available Monday
through Friday, 9 a.m. to 6 p.m. ET, toll free
at (800) 955-4572; email
infocenter@lls.org ; or click the "Live Patient
Help" button on the
www.LLS.org homepage.
| |
|
|
Research
Certain cancer drugs can cause heart
problems. Learn what scientists are doing to
help patients :: READ MORE::
Hematological
Cancer
Updates
New Approach to Help Control
Drug Resistance in Leukemia Identified ::READ MORE::
Non-Hodgkin Patients Living
Longer: Study
::READ MORE::
Combination
Therapy Effective against Multiple
Myeloma
:: READ MORE::
Clinical
Trials
Post-traumatic
stress disorder and risk factors in parents of
children with a cancer diagnosis
:: READ MORE::
Safety and efficacy of
ofatumumab, a fully human monoclonal anti-CD20
antibody, in patients with relapsed or
refractory B-cell chronic lymphocytic leukemia:
a Phase I-II study
:: READ MORE::
Newsfeeds &
Podcasts
Now
you can get RSS Feeds and Podcasts from LLS.
:: CLICK HERE TO SIGN
UP::
Free
eNewsletters
Free LLS
eNewsletters deliver the latest information on
research and treatment options, patient services
programs and fundraising events.
::CLICK HERE TO SIGN UP
::
| | | | | 
| | | |
|
|
Mission
Day Advocates for Cancer
Programs
Cancer advocates took their fight for
improved access to care to the nation's capital
during LLS's annual Mission Day on April 8.
Nearly 300 LLS advocates, staff and volunteers
urged their members of Congress to support and
fund blood cancer research and increase access
to lifesaving clinical trials.
"The voices of our advocacy volunteers
throughout the country are the impetus for
legislation to fund blood cancer research and
education programs," said George Dahlman, senior
vice president, LLS's Office of Public Policy.
"While we have made tremendous progress in the
battle against blood cancers, we must continue
to work toward finding cures."
LLS advocates urged their representatives to
act on a number of fronts, including:
- Increased Access to Clinical Trials
Clinical trials are the roadmaps to blood
cancer cures. However, insurance companies
often deny access to clinical trials by refusing
to cover "routine care costs" - costs that would
be covered in standard therapy. Routine
care costs can include blood tests, doctor
visits and radiological services. This
barrier to access is one of many reasons that
only three to five percent of adult cancer
patients enroll in clinical trials.
- Increased Funding for the National
Institutes of Health and National Cancer
Institute
Reductions in funding for these
agencies have seriously jeopardized recent
cancer research gains. LLS urges the Bush
administration and Congress to provide increased
funding immediately.
- Support Blood Cancer Research at the
U.S. Department of Defense
(DoD)
Until 2007, Congress provided $30
million in DoD funding for chronic myelogenous
leukemia research. LLS is calling for a
dedicated blood cancer research program as part
of the DoD research portfolio, funded at $10
million next fiscal year.
>Back to the
top
Upcoming Myeloma
Teleconference
LLS is pleased to present the
free telephone education program Stem Cell
Transplantation for Myeloma in the Era of Drug
Therapy, 2 p.m. - 3:30 p.m. ET, on
Tuesday, April 22. Register
online.
The
program will feature Edward A. Stadtmauer, M.D.,
professor of medicine, director, Bone Marrow and
Stem Cell Transplant Program and co-leader,
Hematologic Malignancies Program, Abramson
Cancer Center, the University of
Pennsylvania.
While myeloma remains the
most difficult to treat blood cancer, with a
five-year survival rate of only 34 percent,
scientists are making progress. New drug
therapies, including use of Velcade®
and Revlimid®, are often paired with
stem cell transplants to offer greater hope for
patients.
Dr. Stadtmauer will discuss the
role of transplantation in myeloma treatment,
clinical trials, drug therapies and
quality-of-life issues for patients. A
question-and-answer period will follow.
"The more information myeloma patients
have the better decisions they can make in
regard to treatment and side-effect management,"
explained Hildy Dillon, M.P.H., LLS's senior
vice president of patient services. "We
encourage patients, caregivers and healthcare
providers to participate in this informative
program."
In addition to this program,
LLS offers numerous resources to help patients
and their families cope with myeloma. There are
myeloma
pages on our
Web
site, brochures as well as archived
telephone education programs. They may also
order or read online our Understanding Drug
Therapy and Side Effects
brochure.
To
speak with a trained information specialist,
please call the | | | | | | | |
